• LAST PRICE
    0.6799
  • TODAY'S CHANGE (%)
    Trending Up0.0221 (3.3597%)
  • Bid / Lots
    0.5500/ 1
  • Ask / Lots
    0.6881/ 2
  • Open / Previous Close
    0.6931 / 0.6578
  • Day Range
    Low 0.6400
    High 0.6998
  • 52 Week Range
    Low 0.6211
    High 12.9000
  • Volume
    63,111
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.6578
TimeVolumeSABS
10:08 ET1000.6931
10:10 ET1000.6932
10:14 ET2240.693
10:24 ET9850.675
10:26 ET1000.6998
10:28 ET9290.6799
10:32 ET92000.665
10:35 ET10000.6798
11:20 ET10000.65
11:22 ET5000.6502
11:33 ET61630.65
11:40 ET25000.65
11:42 ET218990.650016
11:47 ET52380.65
12:05 ET18520.6517
01:55 ET6750.676299
01:57 ET8000.6726
02:36 ET11000.64
03:09 ET25000.6694
03:34 ET1000.6837
03:45 ET9660.6772
03:52 ET2000.6782
03:59 ET10420.6799
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSABS
SAB Biotherapeutics Inc
29.3M
-1.3x
---
United StatesALIM
Alimera Sciences Inc
37.1M
-2.1x
---
United StatesRMTI
Rockwell Medical Inc
13.6M
-0.1x
---
United StatesBIOQ
Bioqual Inc
69.3M
12.6x
+17.04%
United StatesCDTX
Cidara Therapeutics Inc
47.0M
-0.6x
---
United StatesOPNT
Opiant Pharmaceuticals Inc
54.3M
-2.6x
---
As of 2022-09-25

Company Information

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. The Company uses its immunotherapy platform, DiversitAb, to produce a new class of specifically targeted, fully human polyclonal antibodies without the need for human donors and applies to a range of serious unmet needs in human diseases. The Company's product candidates include SAB-185, which is a fully human polyclonal antibody therapeutic for the treatment of Coronavirus disease (COVID-19), and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. The Company's pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction and early discovery work in oncology.

Contact Information

Headquarters
2100 East 54Th Street North, Suite 202SIOUX FALLS, SD, United States 57104
Phone
605-679-6980
Fax
302-636-5454

Executives

Executive Chairman of the Board
Samuel Reich
President, Chief Executive Officer, Director
Eddie Sullivan
Non-Executive Independent Vice Chairman of the Board
David Link
Chief Financial Officer
Russell Beyer
Chief Operating Officer
Kipp Erickson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$29.3M
Revenue (TTM)
$79.0M
Shares Outstanding
43.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.52
Book Value
$0.89
P/E Ratio
-1.3x
Price/Sales (TTM)
0.4
Price/Cash Flow (TTM)
---
Operating Margin
-32.40%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.